T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecific tetravalent antibody CD19 × CD3 or CD19 × CD16

Cancer Immunology, Immunotherapy

Volumn 61, Issue 10, 2012, Pages 1869-1875

  Pörtner, Lisa M ^a   Schönberg, Kathrin ^a   Hejazi, Maryam ^a   Brünnert, Daniela ^a   Neumann, Frank ^a   Galonska, Lars ^a   Reusch, Uwe ^b   Little, Melvyn ^b   Haas, Rainer ^a   Uhrberg, Markus ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Affimed GmbH   (Germany)

Author keywords

Antibody therapy; Bispecific antibodies; CD19 CD16 TandAb; CD19 CD3 TandAb; NHL

Indexed keywords

BISPECIFIC ANTIBODY; CD19 CD16 ANTIBODY; CD19 CD3 ANTIBODY; CYTOTOXIC AGENT; LENALIDOMIDE; RITUXIMAB; THALIDOMIDE; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; B CELL LYMPHOMA; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; LYMPHOMA CELL; MALE; NATURAL KILLER CELL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; T LYMPHOCYTE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, BISPECIFIC; ANTIGENS, CD19; ANTIGENS, CD3; ANTINEOPLASTIC AGENTS; CELLS, CULTURED; FEMALE; GPI-LINKED PROTEINS; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; RECEPTORS, IGG; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84867580896     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1339-9     Document Type: Article

References (25)

1. Sitzia J, North C, Stanley J, Winterberg N (1997) Side effects of CHOP in the treatment of non-hodgkin's lymphoma. Cancer Nurs 20(6):430-439
2. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4):235-242
3. Chames P, Baty D (2009) Bispecific antibodies for cancer therapy: the light at the end of the tunnel? MAbs 1(6):539-547
4. Fischer N, Leger O (2007) Bispecific antibodies: molecules that enable novel therapeutic strategies. Pathobiology 74(1):3-14. doi: 10.1159/000101046
5. Kipriyanov SM (2009) Generation of bispecific and tandem diabodies. Methods Mol Biol 562:177-193. doi:10.1007/978-1- 60327-302-2-14
6. Scheuermann RH, Racila E (1995) CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk Lymphoma 18(5-6):385-397
7. Loffler A, Kufer P, Lutterbuse R, Zettl F, Daniel PT, Schwenkenbecher JM, Riethmuller G, Dorken B, Bargou RC (2000) A recombinant bispecific single-chain antibody, CD19 9 CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 95(6):2098-2103
8. Hoffmann P, Hofmeister R, Brischwein K, Brandl C, Crommer S, Bargou R, Itin C, Prang N, Baeuerle PA (2005) Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3- bispecific single-chain antibody construct. Int J Cancer 115(1): 98-104
9. Schlereth B, Quadt C, Dreier T, Kufer P, Lorenczewski G, Prang N, Brandl C, Lippold S, Cobb K, Brasky K, Leo E, Bargou R, Murthy K, Baeuerle PA (2006) T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Cancer Immunol Immunother 55(5):503-514
10. Manzke O, Tesch H, Borchmann P, Wolf J, Lackner K, Gossmann A, Diehl V, Bohlen H (2001) Locoregional treatment of low-grade B-cell lymphoma with CD3 9 CD19 bispecific antibodies and CD28 costimulation. I. Clinical phase I evaluation. Int J Cancer 91(4):508-515
11. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M, Einsele H, Brandl C, Wolf A, Kirchinger P, Klappers P, Schmidt M, Riethmuller G, Reinhardt C, Baeuerle PA, Kufer P (2008) Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321(5891):974-977. doi:10.1126/science.1158545
12. Nagorsen D, Bargou R, Ruttinger D, Kufer P, Baeuerle PA, Zugmaier G (2009) Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab. Leuk Lymphoma 50(6):886-891. doi:10.1080/10428190902943077
13. Kipriyanov SM, Cochlovius B, Schafer HJ, Moldenhauer G, Bahre A, Le Gall F, Knackmuss S, Little M (2002) Synergistic antitumor effect of bispecific CD19 9 CD3 and CD19 9 CD16 diabodies in a preclinical model of non-Hodgkin's lymphoma. J Immunol 169(1):137-144
14. Schlenzka J, Moehler TM, Kipriyanov SM, Kornacker M, Benner A, Bahre A, Stassar MJ, Schafer HJ, Little M, Goldschmidt H, Cochlovius B (2004) Combined effect of recombinant CD19 9 CD16 diabody and thalidomide in a preclinical model of human B cell lymphoma. Anticancer Drugs 15(9):915-919
15. Bruenke J, Barbin K, Kunert S, Lang P, Pfeiffer M, Stieglmaier K, Niethammer D, Stockmeyer B, Peipp M, Repp R, Valerius T, Fey GH (2005) Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16). Br J Haematol 130(2):218-228
16. Haagen IA, Geerars AJ, de Lau WB, Bast BJ, de Gast BC (1995) The efficacy of CD3 9 CD19 bispecific monoclonal antibody (BsAb) in a clonogenic assay: the effect of repeated addition of BsAb and interleukin-2. Blood 85(11):3208-3212
17. Reusch U, Le Gall F, Hensel M, Moldenhauer G, Ho AD, Little M, Kipriyanov SM (2004) Effect of tetravalent bispecific CD19 9 CD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cells. Int J Cancer 112(3):509-518
18. Kipriyanov SM, Moldenhauer G, Schuhmacher J, Cochlovius B, Von der Lieth CW, Matys ER, Little M (1999) Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J Mol Biol 293(1):41-56. doi:10.1006/jmbi. 1999.3156
19. Le Gall F, Reusch U, Little M, Kipriyanov SM (2004) Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody. Protein Eng Des Sel 17(4):357-366. doi:10.1093/protein/gzh039
20. Knackmuss S, Molkenthin V (2009) Antibodies from IgM libraries. In: Little M (ed) Recombinant antibodies for immunotherapy. Cambridge University Press, Cambridge, pp 66-74
21. Schonberg K, Sribar M, Enczmann J, Fischer JC, Uhrberg M (2011) Analyses of HLA-C-specific KIR repertoires in donors with group A and B haplotypes suggest a ligand-instructed model of NK cell receptor acquisition. Blood 117(1):98-107. doi: 10.1182/blood-2010-03-273656
22. Mackall CL, Fleisher TA, Brown MR, Magrath IT, Shad AT, Horowitz ME, Wexler LH, Adde MA, McClure LL, Gress RE (1994) Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 84(7):2221-2228
23. Mack M, Gruber R, Schmidt S, Riethmuller G, Kufer P (1997) Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity. J Immunol 158(8):3965-3970
24. Brischwein K, Parr L, Pflanz S, Volkland J, Lumsden J, Klinger M, Locher M, Hammond SA, Kiener P, Kufer P, Schlereth B, Baeuerle PA (2007) Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. J Immunother 30(8):798-807. doi:10.1097/CJI. 0b013e31
25. Hiddemann W, Longo DL, Coiffier B, Fisher RI, Cabanillas F, Cavalli F, Nadler LM, De Vita VT, Lister TA, Armitage JO (1996) Lymphoma classification-the gap between biology and clinical management is closing. Blood 88(11):4085-4089